Recently, the importance of myeloid cells is emerging in lung cancer; in 32 NSCLC patients treated with ICB (pembrolizumab, nivolumab, atezolizumab), a high proportion of myeloid cells expressing PDL-1 (PDL-1+ CD11b+ myeloid cells) was associated with objective response (92). The gene discussed is ITGAM; the disease is non-small cell lung carcinoma.